BDDE (1,4-butanediol diglycidyl ether) is a chemical cross-linking agent used to stabilise hyaluronic acid in dermal fillers. The substance is permitted within regulatory limit values, but residual amounts may remain after the manufacturing process.
LUMIFIL® states 0 % detectable residual BDDE, documented with a certificate. The tests were carried out by the manufacturer LUMIFIL UK, not by an independent third party.
*Based on BC Nordic's own sales figures as exclusive Nordic distributor, and applies to our own range — not the Norwegian filler market as a whole.
**Stated by the manufacturer LUMIFIL UK. Not verified through independent market data.
Choosing a filler with low residual BDDE is about predictability over time.
All three are CE marked medical devices based on cross-linked hyaluronic acid, with 0 % detectable BDDE.
It means that laboratory tests have not detected residual amounts of the cross-linking agent BDDE in the product. The tests were carried out by the manufacturer LUMIFIL UK and are documented with a certificate. In the professional literature, lower residual BDDE is associated with a lower risk of adverse reactions, particularly with repeated treatments over time.
Yes. Lumifil L-Lite, L-Kiss and L-Max are CE marked medical devices and are covered by the EU Medical Device Regulation (MDR) in Norway, Denmark, Sweden and Finland. They are sold to qualified healthcare practitioners and registered clinics, not through pharmacies. BC Nordic is the exclusive distributor of Lumifil in the Nordics.
As the exclusive Nordic distributor, BC Nordic delivers Lumifil directly to verified clinics in Norway, Denmark, Sweden and Finland, with Norwegian customer service and professional support.
The figures for the United Kingdom are stated by the manufacturer LUMIFIL UK and have not been verified through independent market data. The figure for Norway is based on BC Nordic's own sales figures as exclusive distributor, and therefore applies to our own range.
